Is Tyme Technologies Inc (NASDAQ:TYME)’s Fuel Running High? Reports Show Less Sellers

June 13, 2018 - By Ellis Scott

The stock of Tyme Technologies Inc (NASDAQ:TYME) registered a decrease of 18.24% in short interest. TYME’s total short interest was 285,600 shares in June as published by FINRA. Its down 18.24% from 349,300 shares, reported previously. With 163,500 shares average volume, it will take short sellers 2 days to cover their TYME’s short positions. The short interest to Tyme Technologies Inc’s float is 1.14%.

The stock decreased 2.99% or $0.1 during the last trading session, reaching $3.25. About 159,907 shares traded. Tyme Technologies, Inc. (NASDAQ:TYME) has risen 3.14% since June 13, 2017 and is uptrending. It has underperformed by 9.43% the S&P500.

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. The company has market cap of $324.35 million. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. It currently has negative earnings.

More notable recent Tyme Technologies, Inc. (NASDAQ:TYME) news were published by: which released: “Tyme Announces Five Clinical Abstracts at the 2018 ASCO Annual Meeting” on May 17, 2018, also with their article: “Tyme Appoints Pharma Executive Don DeGolyer to Board of Directors” published on May 30, 2018, published: “42 Biggest Movers From Yesterday” on June 13, 2018. More interesting news about Tyme Technologies, Inc. (NASDAQ:TYME) were released by: and their article: “Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use Programs” published on June 12, 2018 as well as‘s news article titled: “Tyme Inc. (TYME) Reports Detailed Data & Analyses with SM-88 on First Human Study & Compassionate Use Programs” with publication date: June 12, 2018.

Tyme Technologies, Inc. (NASDAQ:TYME) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.